Tuesday, 19 Jun 2018

You are here

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source https://buff.ly/2z04f9h)

Using national French National Health Insurance databases, they studied adults with IBD between 2009-2013, with follow-up through 2015; specifically looking for lymphomas associated with thiopurines and anti-TNF agents.

The study included 189,289 patients (median age 43 years) with a medial follow up of 6.7 years. Cohorts included those never exposed (n 123 069), thiopurine monotherapy exposed (n 50405), TNFi exposed (30294), and combination therapy exposed (14229).

For those drug exposed, there were a total of 336 lymphomas and the incidence rate was 0.26 per 1000 person-years (95% CI, 0.23-0.29), The drug-related risks were:

  • thiopurine monotherapy - adjusted hazard ratio [aHR] = 2.60; 95% CI, 1.96-3.44 (P < .001)
  • anti-TNF monotherapy - aHR = 2.41; 95% CI, 1.60-3.64 (P < .001)
  • combination therapy - aHR = 6.11; 95% CI, 3.46-10.8 (P < .001).

Lymphoma subtypes included nonfollicular lymphoma (130 cases, 39%), diffuse large B-cell lymphoma (83 cases); Hodgkin lymphoma (55 cases, 16%); and follicular lymphoma (41, 12%). Hodgkin lymphoma made up 14% of all lymphomas among unexposed patients, 19% among patients exposed to thiopurines, 19% in those exposed to TNF blockers, and 43% in those exposed to combination therapy.

Editor's note: these findings are in line with what has been reported for TNFi previously by the FDA and is reflected in the product label for each TNFi. What is unique here is that in patients with rheumatoid arthritis, the rate of lymphoma was higher (2-6 fold higher) when comparing patients on drug to those in the normal population; but was equal to other RA patients not taking TNFi.  These studies show that in IBD the lymphoma risk was roughly 2.5 fold higher when comparing IBD patient on TNFi or thiopurine to those not taking these aggressive therapies.  While this most likely represents the channeling bias of those with more aggressive disease receiving more aggressive therapy. The authors noted that the benefits of these agents in IBD must be weighed against the absolute risk of < 1 lymphoma per 1000 patient-years of exposure.

In IBD patients the use of thiopurine monotherapy or anti-TNF monotherapy was associated with a small but statistically significant increased risk of lymphoma compared with exposure to neither medication, and this risk was higher with combination therapy than with each of these treatments used alone. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.

MMWR: Cannabis Use in the Colorado Workers

MMWR reports that eight states, including Colorado, have legalized recreational marijuana for use by adults and that a study of use in Colorado has shown that nearly 15% of Colorado adult workers have used marijuana in the past 30 days. Use was highest among young adults, especially men, working in the Accommodation/Food Services and Food Preparation/Serving industries.